Table 1.
Patients’ characteristics undergoing sRP before IRE treatment and IRE treatment characteristics.
| Characteristic | Value |
|---|---|
| Number of patients | 39 |
| Age at time of IRE, years, median (IQR) | 64 (60–67) |
| Pre‐IRE PSA levels, ng/mL, median (IQR) | 6.0 (4.9–8.1) |
| Prostate volume pre‐IRE, mL, mean (sd) | 45 (17.5) |
| ASA classification, n (%) | |
| I | 17 (43.6) |
| II | 20 (51.3) |
| III | 2 (5.1) |
| ISUP GG, n (%) | |
| 1 | 10 (25.6) |
| 2 | 25 (64.1) |
| 3 | 4 (10.3) |
| Number of biopsy cores, median (IQR) | 20 (12–30) |
| Number of positive cores, median (IQR) | 3 (2–4.5) |
| T‐staging, n (%) | |
| T1c | 24 (61.5) |
| T2a–b | 14 (35.9) |
| T2c | 1 (2.6) |
| D’Amico risk classification, n (%) | |
| Low‐risk disease | 7 (18.0) |
| Intermediate‐risk disease | 31 (79.5) |
| High‐risk disease | 1 (2.6) |
| IRE treatment site, n (%) | |
| Left apex | 11 (28.2) |
| Left base/mid | 7 (17.9) |
| Right apex | 7 (17.9) |
| Right base/mid | 10 (25.6) |
| Multifocal | 4 (10.3) |
| IRE treatment location, n (%) | |
| Unilateral | 33 (84.6) |
| Bilateral | 6 (15.4) |
| IRE needles used, median (IQR) | |
| During first treatment | 4 (3–4) |
| During second treatment (n = 7) | 4 (3–4) |
| Time to second IRE treatment, months, median (IQR) | 29.8 (12.2–50.5) |
ASA, American Society of Anesthesiology.